Literature DB >> 23439102

Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.

Friedrich W Mohr1, Marie-Claude Morice, A Pieter Kappetein, Ted E Feldman, Elisabeth Ståhle, Antonio Colombo, Michael J Mack, David R Holmes, Marie-angèle Morel, Nic Van Dyck, Vicki M Houle, Keith D Dawkins, Patrick W Serruys.   

Abstract

BACKGROUND: We report the 5-year results of the SYNTAX trial, which compared coronary artery bypass graft surgery (CABG) with percutaneous coronary intervention (PCI) for the treatment of patients with left main coronary disease or three-vessel disease, to confirm findings at 1 and 3 years.
METHODS: The randomised, clinical SYNTAX trial with nested registries took place in 85 centres in the USA and Europe. A cardiac surgeon and interventional cardiologist at each centre assessed consecutive patients with de-novo three-vessel disease or left main coronary disease to determine suitability for study treatments. Eligible patients suitable for either treatment were randomly assigned (1:1) by an interactive voice response system to either PCI with a first-generation paclitaxel-eluting stent or to CABG. Patients suitable for only one treatment option were entered into either the PCI-only or CABG-only registries. We analysed a composite rate of major adverse cardiac and cerebrovascular events (MACCE) at 5-year follow-up by Kaplan-Meier analysis on an intention-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT00114972.
FINDINGS: 1800 patients were randomly assigned to CABG (n=897) or PCI (n=903). More patients who were assigned to CABG withdrew consent than did those assigned to PCI (50 vs 11). After 5 years' follow-up, Kaplan-Meier estimates of MACCE were 26·9% in the CABG group and 37·3% in the PCI group (p<0·0001). Estimates of myocardial infarction (3·8% in the CABG group vs 9·7% in the PCI group; p<0·0001) and repeat revascularisation (13·7%vs 25·9%; p<0·0001) were significantly increased with PCI versus CABG. All-cause death (11·4% in the CABG group vs 13·9% in the PCI group; p=0·10) and stroke (3·7%vs 2·4%; p=0·09) were not significantly different between groups. 28·6% of patients in the CABG group with low SYNTAX scores had MACCE versus 32·1% of patients in the PCI group (p=0·43) and 31·0% in the CABG group with left main coronary disease had MACCE versus 36·9% in the PCI group (p=0·12); however, in patients with intermediate or high SYNTAX scores, MACCE was significantly increased with PCI (intermediate score, 25·8% of the CABG group vs 36·0% of the PCI group; p=0·008; high score, 26·8%vs 44·0%; p<0·0001).
INTERPRETATION: CABG should remain the standard of care for patients with complex lesions (high or intermediate SYNTAX scores). For patients with less complex disease (low SYNTAX scores) or left main coronary disease (low or intermediate SYNTAX scores), PCI is an acceptable alternative. All patients with complex multivessel coronary artery disease should be reviewed and discussed by both a cardiac surgeon and interventional cardiologist to reach consensus on optimum treatment. FUNDING: Boston Scientific.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23439102     DOI: 10.1016/S0140-6736(13)60141-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  272 in total

1.  Description of a Heart Team approach to coronary revascularization and its beneficial long-term effect on clinical events after PCI.

Authors:  Tassilo Bonzel; Volker Schächinger; Hilmar Dörge
Journal:  Clin Res Cardiol       Date:  2015-10-27       Impact factor: 5.460

2.  [ESC guidelines 2015. Non-ST-elevation acute coronary syndrome].

Authors:  A Jobs; H Thiele
Journal:  Herz       Date:  2015-12       Impact factor: 1.443

3.  The N-terminus of HIV-1 Tat protein is essential for Tat-TAR RNA interaction.

Authors:  O Chaloin; J-C Peter; J-P Briand; B Masquida; C Desgranges; S Muller; J Hoebeke
Journal:  Cell Mol Life Sci       Date:  2005-02       Impact factor: 9.261

4.  Contemporary Use and Trends in Unprotected Left Main Coronary Artery Percutaneous Coronary Intervention in the United States: An Analysis of the National Cardiovascular Data Registry Research to Practice Initiative.

Authors:  Javier A Valle; Hector Tamez; J Dawn Abbott; Issam D Moussa; John C Messenger; Stephen W Waldo; Kevin F Kennedy; Frederick A Masoudi; Robert W Yeh
Journal:  JAMA Cardiol       Date:  2019-02-01       Impact factor: 14.676

Review 5.  Coronary artery disease and diabetes mellitus.

Authors:  Doron Aronson; Elazer R Edelman
Journal:  Cardiol Clin       Date:  2014-06-10       Impact factor: 2.213

6.  Composite outcomes in coronary bypass surgery versus percutaneous intervention.

Authors:  Fred H Edwards; David M Shahian; Maria V Grau-Sepulveda; Frederick L Grover; John E Mayer; Sean M O'Brien; Elizabeth DeLong; Eric D Peterson; Charles McKay; Richard E Shaw; Kirk N Garratt; George D Dangas; John Messenger; Lloyd W Klein; Jeffrey J Popma; William S Weintraub
Journal:  Ann Thorac Surg       Date:  2014-04-26       Impact factor: 4.330

7.  A prospective study of patients with refractory angina: outcomes and the role of high-sensitivity troponin T.

Authors:  Nilson T Poppi; Luís H W Gowdak; Luciana O C Dourado; Eduardo L Adam; Thiago N P Leite; Bruno M Mioto; José E Krieger; Luiz A M César; Alexandre C Pereira
Journal:  Clin Cardiol       Date:  2016-10-18       Impact factor: 2.882

8.  Impact of drug-eluting stents on the comparative effectiveness of coronary artery bypass surgery and percutaneous coronary intervention.

Authors:  Mark A Hlatky; Derek B Boothroyd; Laurence C Baker; Alan S Go
Journal:  Am Heart J       Date:  2014-10-25       Impact factor: 4.749

Review 9.  Antagonist molecules in the treatment of angina.

Authors:  Ashish K Gupta; David Winchester; Carl J Pepine
Journal:  Expert Opin Pharmacother       Date:  2013-09-18       Impact factor: 3.889

Review 10.  Optimal revascularization for complex coronary artery disease.

Authors:  Javaid Iqbal; Patrick W Serruys; David P Taggart
Journal:  Nat Rev Cardiol       Date:  2013-09-17       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.